Bladder Cancer - Results from #60

Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer. May 7, 2021

Avelumab for Use as a Bladder Cancer Maintenance Treatment Not Recommended by NHS in England May 6, 2021

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. May 6, 2021

Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. May 6, 2021

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. May 5, 2021

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. May 5, 2021

Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates May 4, 2021

Clinical use of machine learning-based patho-mics signature for diagnosis and survival prediction of bladder cancer. May 4, 2021

Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer. May 4, 2021

Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort. May 3, 2021

Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience. May 3, 2021

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors May 1, 2021

Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Primary Adenocarcinoma of Bladder and Urothelial Carcinoma with Glandular Differentiation - Expert Commentary April 30, 2021

Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration. April 30, 2021

Rapidly Progressing Urothelial Carcinoma Due to a Rare TP53 (p.Arg110Pro) Mutation: A Case Report and Review of the Literature. April 30, 2021

Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications April 29, 2021

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. April 29, 2021

Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. April 29, 2021

Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians. April 28, 2021

Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing? April 28, 2021

Page 4 of 396